Skip to main content
OMDAOmada Health, Inc.Hold6.3·$21.37
HoldModerate Confidence
Investment thesis

Omada Health is growing revenue rapidly with a perfect 4-quarter earnings beat streak, but the stock is technically overbought, has already exceeded its price target, and notable insider selling adds a cautionary signal.

Thesis pillars

  • Strong Revenue GrowthStable
  • Overbought Late Cycle RiskImproving
  • Notable Insider SellingStable
  • +2 more pillars — see the Why tab for full reasoning

Full reasoning →

Open full analysis

Omada Health, Inc. (OMDA) Stock Analysis

Range Bound setup

HoldVALUE-TRAP 2/5GrowthModerate Confidence

Healthcare · Health Information Services

Hold if already holding. Not a fresh buy at $21.37, but acceptable to hold if already in. Reason: Value-trap signals (2/5): Margin compression (op margin 4.0%), Material insider selling (33 sells, 0.39% of cap).

Omada Health, Inc., together with its subsidiary, Physera, Inc., provides a range of virtual care programs in the United States. The company offers cardiometabolic programs for prediabetes, diabetes, and hypertension; a physical therapy program to address musculoskeletal... Read more

$21.37+15.7% A.UpsideScore 6.3/10#3 of 23 Health Information Services
QualityF-score8 / 9FCF yield0.91%
Stop $19.87Target $24.72(analyst − 13%)A.R:R 1.5:1
Analyst target$28.42+33.0%12 analysts
$24.72our TP
$21.37price
$28.42mean
$35

Hold if already holding. Not a fresh buy at $21.37, but acceptable to hold if already in. Reason: Value-trap signals (2/5): Margin compression (op margin 4.0%), Material insider selling (33 sells, 0.39% of cap). Chart setup: RSI 41 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Score 6.3/10, moderate confidence.

Passes 7/9 gates (positive momentum, favorable risk/reward ratio, no SEC red flags, news events none recent, earnings proximity 43d clear, semi cycle peak clear, materials cycle peak clear). Fails on clean insider activity. Suitability: aggressive.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated 2026-09-23
TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Thu, Nov 5, 202643d to earnings· next earnings call

Thesis

Rewards
Sector modifier (Healthcare): +0.5
Strong earnings beat streak (4/4)
Strong growth profile
Risks
Value-trap signals (2/5): Margin compression (op margin 4.0%), Material insider selling (33 sells, 0.39% of cap)

Key Metrics

P/E (TTM)31.0
P/E (Fwd)38.4
Mkt Cap$1.3B
EV/EBITDA200.1
Profit Mgn1.4%
ROE1.8%
Rev Growth43.1%
Beta
DividendNone
Rating analysts18

Quality Signals

Piotroski F8/9MoatNarrow

Options Flow

P/C0.83neutral
IV61%elevated

Concentration Risks(10-K Item 1A)

  • MEDIUMCustomerlimited number of customers and channel partners
    10-K Item 1A: 'A substantial portion of our sales comes from or through a limited number of customers and channel partners that operate as resellers.'
  • MEDIUMSupplierlimited number of third-party suppliers
    10-K Item 1A: 'We depend on a limited number of third-party suppliers for certain devices and other supplies that we deliver to members in connection with our programs'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

1 ceiling hit

GatesINSIDER 0.39%=HEAVYMomentum 4.7<5.5 (soft — BUY_NOW allowed but watch)Momentum 4.7>=4.5A.R:R 1.5 ≥ 1.5No SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 43d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRange BoundSuitability: Aggressive
RSI
41 · Neutral
20D MA 50D MA 200D MAGOLDEN CROSSSupport $19.31Resistance $25.45

Price Targets

$20
$25
A.Upside+15.7%
A.R:R1.5:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeRisk-Off

Risk Alerts

! Insider activity: 0.39%=heavy

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-11-05 (43d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is OMDA stock a buy right now?

Hold if already holding. Not a fresh buy at $21.37, but acceptable to hold if already in. Reason: Value-trap signals (2/5): Margin compression (op margin 4.0%), Material insider selling (33 sells, 0.39% of cap). Chart setup: RSI 41 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Target $24.72 (+15.7%), stop $19.87 (−7.5%), A.R:R 1.5:1. Score 6.3/10, moderate confidence.

What is the OMDA stock price target?

Take-profit target: $24.72 (+15.7% upside). Target $24.72 (+15.7%), stop $19.87 (−7.5%), A.R:R 1.5:1. Stop-loss: $19.87.

What are the risks of investing in OMDA?

Value-trap signals (2/5): Margin compression (op margin 4.0%), Material insider selling (33 sells, 0.39% of cap).

Is OMDA overvalued or undervalued?

Omada Health, Inc. trades at a P/E of 31.0 (forward 38.4). TrendMatrix value score: 5.4/10. Verdict: Hold.

What do analysts say about OMDA?

18 analysts cover OMDA with a consensus score of 4.0/5. Average price target: $28.

What does Omada Health, Inc. do?Omada Health, Inc., together with its subsidiary, Physera, Inc., provides a range of virtual care programs in the...

Omada Health, Inc., together with its subsidiary, Physera, Inc., provides a range of virtual care programs in the United States. The company offers cardiometabolic programs for prediabetes, diabetes, and hypertension; a physical therapy program to address musculoskeletal conditions; other support programs for members taking glucagon-like peptide-1 agonists in its cardiometabolic program; and weight management programs, as well as various behavioral health support programs. It also delivers virtual care. The company offers its programs for employers, health plans and systems, and pharmacy benefits managers through its direct sales force and channel partners. The company was incorporated in 2011 and is headquartered in South San Francisco, California.

Related stocks: HNGE (Hinge Health, Inc.) · CARL (Carlsmed, Inc.) · HQY (HealthEquity, Inc.) · BTSG (BrightSpring Health Services, I) · PRVA (Privia Health Group, Inc.)
Home Stocks OMDA

Latest news

Latest News

MarketBeat35d ago
MarketBeat35d ago
MarketBeat42d ago
MarketBeat42d ago
Investing.com42d ago
MarketBeat42d ago
Seeking Alpha42d agoEarnings
MarketBeat42d agoAnalyst
MarketBeat36d ago
MarketBeat43d ago
Investing.com India44d agoAnalyst
The Globe and Mail41d agoAnalyst
Yahoo Finance45d ago
MarketBeat39d ago
MarketBeat46d agoAnalyst
Sahm46d agoEarnings
Kalkine37d ago
Vinanet37d ago
Vinanet37d ago
MarketBeat40d ago
Loading more...